Atezolizumab Plus Chemo Falters in Rapidly Relapsing TNBC

No difference in survival versus chemotherapy alone in patients with PD-L1-positive disease

Related Keywords

Dana Farber Cancer Institute ,Massachusetts ,United States ,Berlin ,Germany ,Singapore ,Boston ,Saram Tolaney ,Mike Bassett ,Genentech ,National Cancer Center Singapore ,European Society ,Medical Oncology Breast Cancer Congress ,